AstraZeneca stock took a nosedive Monday amid reports it's mulling a mega-merger with Bristol Myers Squibb.
AstraZeneca Stock Nosedives On Mega-Merger Rumor
Licensing
09:14 AM ET 08/03/2026
AstraZeneca (AZN) stock took a nosedive Monday amid reports it's mulling a mega-merger with Bristol Myers Squibb (BMY). The combined company would be worth roughly $400 billion, "making it one of the biggest pharmaceutical mergers in history," RBC Capital Markets analyst Trung Huynh said in a report. The Financial Times first reported the early merger talks. AstraZeneca declined to comment…
AstraZeneca share prices drop amid £300bn mega-merger talks with US rival
An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
AstraZeneca shares fall amid reports of $400bn Bristol Myers Squibb merger talks
AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger - AstraZeneca (NYSE:AZN)
AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
Why Is Bristol-Myers Squibb Stock Surging Monday? - Bristol-Myers Squibb (NYSE:BMY), AstraZeneca (NYSE:AZ
AstraZeneca said to have explored Bristol Myers merger | Fortune
AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus - Bristol-Myers
AstraZeneca, Bristol Myers are in talks about merger — report
AstraZeneca in talks over £300bn mega-merger with US rival – reports
The merger would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company
In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the…
Analysts warn mega-merger risks undermine AstraZeneca’s growth and innovation strategy
AstraZeneca in talks to merge with Bristol Myers Squibb, creating $400B pharma giant, while talks ongoing for months, antitrust…
AstraZeneca shares dropped as much as 7% after a report that the U.K.'s largest drugmaker was in talks with U.S. peer Bristol…
Bristol Myers Squibb and AstraZeneca in talks for a $400B mega-merger, potentially creating the world's 4th-largest drugmaker.
